Portal de investigação
Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Almeida, LM
- Fernandes, AL
- Cardoso, CG
- Lima, B
- Neves, I
- Mota, PC
- Melo, N
- Moura, CS
- Guimaraes, S
- Carvalho, A
- Cunha, R
- Pereira, JM
Unidades de investigação
Abstract
Background:Fibrotic hypersensitivity pneumonitis (fHP) is associated with significant morbidity and mortality. Interstitial lung disease-gender-age-physiology (ILD-GAP) performance in fHP outside the initial cohort was never performed. Aim:To assess the ILD-GAP index's ability to predict mortality in a Portuguese cohort of patients with fHP and analyse whether other clinical variables add value. Methods:Retrospective analysis of fHP cohort in two Portuguese ILD centres. The baseline ILD-GAP index was calculated. Survival was analysed in months; mortality was the primary outcome. Univariate and multivariate analyses to identify mortality risk factors were performed. Results:A total of 141 patients were included. Fifty-three patients (37.6%) died during the follow-up. The usual interstitial pneumonia (UIP) pattern was found in 49.6%, and their survival was inferior to non-UIP [32 months (interquartile range, IQR = 19, 60) versus 52 months (IQR = 28, 98), p = 0.048]. Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = (3.03-13.96)] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = (1.62-5.71)] adjusting for acute exacerbation history. Even though UIP patients had worse survival, it did not reach statistical significance when UIP pattern was added to this model. Acute exacerbation history was an independent risk factor for mortality; however, ILD-GAP still predicted mortality after adjusting for this factor. PaO2 and 6-minute walk test desaturation were not significant risk factors. Conclusion:ILD-GAP index is a good predictor for mortality in fHP, even after adjusting for other mortality risk factors.
Dados da publicação
- ISSN/ISSNe:
- 1753-4658, 1753-4666
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Therapeutic Advances in Respiratory Disease SAGE Publications Ltd
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 7
Documentos
- Não há documentos
Filiações
Keywords
- chronic hypersensitivity pneumonitis; fibrotic interstitial lung disease; ILD-GAP
Proyectos asociados
Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032
Investigador Principal: Hélder Novais e Bastos
Estudo Observacional Académico (FIBRALUNG) . FCT . 2021
Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Impact of Chronic Obstructive Pulmonary Disease in surgical outcomes of lung cancer patients undergoing curative intent surgery
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2021
Pulmonary Emphysema Regional Distribution and Extent from Chest Computed Tomography is Associated with Pulmonary Function Impairment in COPD Patients.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2021
Non-invasive assessment of Benign Tracheal Stenosis.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Citar a publicação
Almeida LM,Fernandes AL,Cardoso CG,Lima B,Neves I,Novais H,Mota PC,Melo N,Moura CS,Guimaraes S,Carvalho A,Cunha R,Pereira JM,Morais A. Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort. Ther. Adv. Respir. Dis. 2022. 16. 17534666221135316. IF:4,300. (2).
